

Supplementary Materials

Supplementary Table S1 Type of treatment initiated in 95 patients with 101 events with 195 neuropsychiatric manifestations

	Total number	Induction & maintenance therapy (n, %)	Methyl-prednisolone (n, %)	Azathioprine (n, %)	Cyclophosphamide (n, %)
1999 ACR NPSLE syndromes					
Aseptic meningitis	1	1 (100)	1 (100)	0 (0)	1 (100)
Cerebrovascular disease	31	26 (84)	17 (55)	15 (48)	15 (48)
Demyelinating syndrome	0	-	-	-	-
Headache	11	10 (91)	4 (36)	9 (81)	1 (19)
Movement disorder (chorea)	4	2 (50)	1 (25)	2 (50)	0 (0)
Myelopathy	11	7 (63)	10 (91)	1 (9)	8 (73)
Seizure disorders	8	8 (100)	3 (38)	6 (75)	3 (38)
Acute confusional state	10	7 (70)	10 (100)	4 (40)	7 (70)
Anxiety disorder	2	1 (50)	0 (0)	1 (50)	0 (0)
Cognitive dysfunction	50	39 (78)	20 (40)	26 (52)	21 (42)
Mood disorder	15	10 (67)	5 (33)	10 (67)	6 (40)
Psychosis	8	3 (38)	5 (63)	1 (13)	3 (38)
AIDP	0	-	-	-	-
Autonomic disorder	1	1 (100)	0 (0)	0 (0)	0 (0)
Mononeuropathy	2	1 (50)	1 (50)	0 (0)	0 (0)
Myasthenia gravis	0	-	-	-	-
Neuropathy, cranial	9	7 (78)	8 (89)	4 (44)	5 (56)
Plexopathy	0	-	-	-	-
Polyneuropathy	8	5 (63)	3 (38)	3 (38)	3 (38)
Other than 1999 ACR syndromes	24	21 (88)	16 (67)	14 (61)	13 (56)
Cerebral vasculitis	10	9 (90)	8 (80)	6 (60)	6 (60)
Organic brain syndrome /lethargy	4	3 (75)	1 (25)	2 (50)	3 (75)
(Pyramidal) walking disorder	4	4 (100)	2 (50)	3 (75)	2 (50)
Ocular problems, other	2	2 (100)	2 (100)	2 (100)	1 (50)
Increased cranial pressure	1	0 (0)	1 (100)	1 (100)	0 (0)
Paresis left arm and dysarthria	1	1 (100)	1 (100)	0 (0)	0 (0)
Motor disorder left arm	1	1 (100)	0 (0)	0 (0)	0 (0)
Apraxia	1	1 (100)	1 (100)	0 (0)	1 (100)
Clinical outcome (% improvement per type of therapy)					
Short-term	-	55/73 (75)	46/54 (85)	32/49 (65)	35/43 (81)
Long-term	-	44/59 (75)	32/44 (73)	24/34 (71)	25/36 (70)

AIDP = acute inflammatory demyelinating polyneuropathy

Supplementary Table S2 Number of total neuropsychiatric manifestations (n = 169) in which clinical improvement was present over time after exclusion of events (n = 13 with 26 NPSLE manifestations) in which the diagnosis was retracted

	Short-term		Long-term		% improvement maintenance vs other therapy
	Total number	Improvement (n, %)	Total number	Improvement (n, % of syndromes)	
1999 ACR NPSLE syndromes					
Aseptic meningitis	1	1 (100)	1	1 (100)	100 vs -
Cerebrovascular disease	27	23 (85)	21	17 (81)	85 vs 0
Demyelinating syndrome	0	-	0	-	-
Headache	8	8 (100)	6	6 (100)	100 vs 100
Movement disorder (chorea)	3	2 (67)	2	1 (50)	50 vs -
Myelopathy	11	11 (100)	9	8 (89)	86 vs 100
Seizure disorders	8	5 (71)	5	2 (40)	40 vs -
Acute confusional state	10	10 (100)	7	7 (100)	100 vs 100
Anxiety disorder	2	1 (50)	1	1 (100)	100 vs -
Cognitive dysfunction	37	29 (78)	30	19 (63)	63 vs 67
Mood disorder	13	9 (69)	10	7 (70)	67 vs 75
Psychosis	8	8 (100)	7	6 (86)	100 vs 80
AIDP	0	-	0	-	-
Autonomic disorder	1	0 (0)	1	1 (100)	100 vs -
Mononeuropathy	2	1 (50)	1	1 (100)	100 vs -
Myasthenia gravis	0	-	0	-	-
Neuropathy, cranial	9	8 (89)	7	6 (75)	71 vs 100
Plexopathy	0	-	0	-	-
Polyneuropathy	6	4 (67)	6	4 (67)	80 vs 0
Other than 1999 ACR syndromes	23	19 (83)	20	16 (80)	
Cerebral vasculitis	9	8 (89)	8	7 (88)	100 vs 0
Organic brain syndrome/lethargy	4	3 (75)	3	2 (67)	67 vs -
(Pyramidal) walking disorder	4	3 (75)	3	1 (33)	33 vs -
Ocular problems, other	2	1 (50)	2	2 (100)	100 vs -
Increased cranial pressure	1	1 (100)	1	1 (100)	- vs 100
Paresis left arm and dysarthria	1	1 (100)	1	1 (100)	100 vs -
Motor disorder left arm	1	1 (100)	1	1 (100)	100 vs -
Apraxia	1	1 (100)	1	1 (100)	100 vs -
Total	169	139 (82)	133	103 (77)	-

AIDP = acute inflammatory demyelinating polyneuropathy